Universal Biosensors Inc (ASX: UBI) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Universal Biosensors Inc Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $31.24 million
P/E Ratio 0.78
Dividend Yield 0.00%
Shares Outstanding 231.40 million
Earnings per share -0.030
Dividend per share N/A
Year To Date Return -32.50%
Earnings Yield 128.47%
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Universal Biosensors Inc (ASX: UBI)
    Latest News

    A woman jumps for joy with a rocket drawn on the wall behind her.
    Healthcare Shares

    This ASX healthcare stock is up 72% on FDA news and 'historic moment'

    Huge gains are been recorded by this stock on Tuesday. But why?

    Read more »

    A female scientist sits at a microscope in a Universal Biosensors laboratory smiling while her colleague checks beakers of COVID-19 samples in the background.
    Healthcare Shares

    Universal Biosensors (ASX:UBI) share price up on "global first" 30-second COVID-19 test

    This micro-cap biotech has big news for ASX investors today.

    Read more »

    A boy looks up and points his fingers to the sky in celebration pose.
    Healthcare Shares

    Why the Universal Biosensors (ASX:UBI) share price is climbing 7% today

    Universal is gaining traction from its Sentia devices...

    Read more »

    falling asx share price represented by woman making sad face
    Healthcare Shares

    Universal Biosensors (ASX:UBI) share price falls despite positive update

    The Universal Biosensors (ASX: UBI) share price is in negative territory today despite a positive update. We take a closer…

    Read more »

    A doctor looks unsure, indicating share price uncertainty for ASX medical companies
    Share Market News

    Universal Biosensors (ASX:UBI) share price dips despite latest update

    The Universal Biosensors Inc. (ASX: UBI) share price is edging lower today despite the company making further expansions overseas.

    Read more »

    man bending over to look at red arrow crashing down through the ground
    Share Market News

    Universal Biosensors (ASX:UBI) share price sinks despite new deal

    The Universal Biosensors, Inc (ASX: UBI) share price is in negative territory despite announcing a distribution deal. Here's the details.

    Read more »

    wine share price rising represented by two people raising wine glasses
    Share Gainers

    Why the Universal Biosensors (ASX:UBI) share price is up 6% today

    The Universal Biosensors (ASX: UBI) share price is climbing today, with news of an agreement for its wine testing device…

    Read more »

    Young doctor raising arms in air with hands in fists celebrating a new development
    Healthcare Shares

    Here's why the Universal Biosensors (ASX:UBI) share price is soaring 10%

    The Universal Biosensor Incorporated (ASX: UBI) share price is up 8% this morning after news of a deal with Deakin…

    Read more »

    Medical staff wear hero capes, indicting strong shar [price performace for healthcare shares
    Share Market News

    Why the Universal Biosensors (ASX:UBI) share price is shooting 36% higher today

    The Universal Biosensors(ASX: UBI) share price is rocketing today after the company made two important announcements to the ASX.

    Read more »

    rising ASX share price represented by cork popping out of wine bottle
    Healthcare Shares

    Universal Biosensors (ASX:UBI) share price is lifting today. Here's why

    The Universal Biosensors share price is rising today after the company signed a Canadian distribution agreement for its wine testing…

    Read more »

    Young doctor raising arms in air with hands in fists celebrating a new development
    Share Market News

    Why the Universal (ASX:UBI) share price is on the run today

    The Universal Biosensors Inc. (ASX: UBI) share price is on the run today. This comes as the company’s Canadian subsidiary…

    Read more »

    hand on touch screen lit up by a share price chart moving higher
    Share Market News

    Why the Universal Biosensors (ASX:UBI) share price is up 5% today

    The Universal Biosensors, Inc. (ASX: UBI) share price has lifted today. This comes after the company announced that it has…

    Read more »

    UBI ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Universal Biosensors Inc

    Universal Biosensors Inc is biosensor company in electrochemical cell technology to develop a diverse range of biosensor test strips. The company's platform develops a diverse range of biosensor test strips used in conjunction with point-of-use devices that are used in various industries such as healthcare (point-of-care), wine, food and agriculture. It manufactures and distributes PT-INR coagulation test strips and devices, Xprecia, Stride and Xprecia Prime which are medical devices, Sentia non-medical wine testing products, and Petrackr which is a blood glucose test used in cats and dogs. Geographically, the company generates majority of its revenue from Australia and rest from Americas, Europe and other markets.

    UBI Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    17 May 2024 $0.14 $0.00 0.00% 309,979 $0.14 $0.14 $0.14
    16 May 2024 $0.14 $-0.01 -7.14% 23,019 $0.14 $0.14 $0.14
    15 May 2024 $0.14 $0.00 0.00% 371,432 $0.14 $0.14 $0.14
    14 May 2024 $0.14 $0.01 7.69% 413,671 $0.14 $0.14 $0.14
    13 May 2024 $0.13 $0.00 0.00% 184,338 $0.13 $0.13 $0.13
    10 May 2024 $0.13 $0.00 0.00% 202,700 $0.14 $0.14 $0.13
    09 May 2024 $0.13 $-0.02 -13.33% 684,026 $0.14 $0.14 $0.13
    08 May 2024 $0.15 $-0.01 -6.25% 1,258,281 $0.15 $0.15 $0.13
    07 May 2024 $0.16 $0.01 6.67% 100,129 $0.15 $0.16 $0.15
    06 May 2024 $0.15 $-0.01 -6.45% 83,650 $0.16 $0.16 $0.15
    03 May 2024 $0.16 $0.01 6.67% 92,967 $0.16 $0.16 $0.16
    02 May 2024 $0.15 $0.00 0.00% 491,501 $0.15 $0.15 $0.14
    01 May 2024 $0.15 $0.00 0.00% 132,556 $0.15 $0.15 $0.15
    30 Apr 2024 $0.15 $-0.01 -6.45% 263,878 $0.16 $0.16 $0.15
    29 Apr 2024 $0.16 $0.01 6.67% 218,814 $0.16 $0.16 $0.16
    26 Apr 2024 $0.15 $-0.02 -11.76% 9,553,691 $0.17 $0.17 $0.15
    23 Apr 2024 $0.17 $0.01 6.06% 73,977 $0.17 $0.17 $0.17
    22 Apr 2024 $0.17 $0.00 0.00% 78,614 $0.17 $0.17 $0.17

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    08 May 2024 Craig Coleman Issued 43,356,173 $6,503,425
    Rights issue.
    08 May 2024 Craig Coleman Issued 29,506,606 $4,425,991
    Rights issue.
    03 May 2024 Judith Smith Issued 99,077 $14,861
    Rights issue. CDIs
    03 May 2024 Graham McLean Issued 180,116 $27,017
    Rights issue. CDIs
    25 Mar 2024 Craig Coleman Exercise 1,000,000 $200,000
    Exercise of options.
    25 Mar 2024 Craig Coleman Buy 1,000,000 $200,000
    Exercise of options. CDIs
    11 Dec 2023 Graham McLean Buy 75,000 $14,901
    On-market trade.
    11 Sep 2023 Craig Coleman Buy 100,000 $22,000
    On-market trade. CDIs
    30 Jun 2023 David Hoey Buy 95,983 $16,119
    On-market trade. CDIs

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Craig Evan Coleman Non-Executive Director Jun 2016
    Mr Coleman is an experienced investment and funds management executive. His career of 30 years has spanned banking and finance, corporate advisory and funds management. Craig is currently the Executive Chairman of Viburnam Funds. During his executive career, Mr Coleman has held a number of senior executive positions with ANZ Banking Group Ltd, including Managing Director Banking Products, Managing Director Wealth Management, Non-Executive Director E TRADE Australia Ltd and Head of Retail Banking New Zealand. Mr Coleman currently retains non-executive directorship position with publicly listed entity Bell Financial Group Limited and is Chairman of Pacific Star Network Limited.

    Ms Judith Ann Smith Non-Executive Director Mar 2015
    Ms Smith is experienced investment and funds management executive. During her career, Ms Smith has worked in a number of investment management roles in the funds management industry, where she has been responsible for evaluating and investing in listed and unlisted companies. Ms Smith was formerly the Head of Private Equity at IFM Investors and Chair of the IFM Risk Committee. Ms Smith was also a member of the IFM Investments Committee, a role she has retained following her retirement from the firm. Prior to her role at IFM, Ms Smith held investment management roles including more than a decade at National Mutual Funds Management Ltd (NMFM). At NMFM, she managed Australian equity research and strategy, as well as Australian equity portfolios. Ms Smith is a member of the Audit Committee of the Australian Renewable Energy Authority. She is a trustee director of industry superannuation fund, LUCRF and the Chairperson of the LUCRF Investment Committee. She is a member of the advisory committee for the SA Venture Capital Fund. She is also a board member of Scale Investors Ltd. In July 2018, Ms Smith was appointed to the board of Funds S4.
    Mr David Leslie Hoey Non-Executive Director Mar 2016
    Mr. Hoey has more than 25 years' experience in technology financing and commercialization. Mr. Hoey is a US-based director and his primary expertise is in business development, strategic planning, market development, corporate partnering and financings for medical technologies, diagnostics and drug development. Mr. Mr. Hoey is currently Chief Executive Office and a director of Vaxxas, Inc. During his career Mr. Hoey has worked in management and leadership roles in the preclinical development of small molecule and biologic therapeutics, molecular diagnostic assays and platforms, and analytical instrumentation. Mr. Hoey served as vice president of business development at PathoGenetix, Inc.

    Mr Graham McLean Non-Executive DirectorNon-Executive Chairman Mar 2022
    Mr McLean has more than 20 years' business and corporate governance experience and is an experienced senior executive leader with service in the medical technology industry in Australia, Asia and US, most recently with Stryker Corporation ('Stryker') as President Asia Pacific. Whilst at Stryker, Mr McLean led a transformation of Asia Pacific to renew growth in Japan and China and led an accelerated growth strategy for Australia/New Zealand. Prior to his time with Stryker, Mr McLean was Lion Nathan's Finance Director International/Business Development and Director Group Risk Assurance & Audit. Since 2021, Mr McLean has served as an Independent Director and Chairman of the Audit and Risk Committee at both Suicide Prevention Australia and also is an Advisor to Bain & Company. He has also previously served on industry boards in Australia (Medical Technology Association of Australia), Japan (American Medical Devices & Diagnostics Manufacturers Association) and Asia Pacific where he was Vice Chairman of the Asia Pacific Medical Technology Association. Mr McLean has - Delivered a recovery for Stryker's business in Japan; Rebuilt the Stryker China business with an investment and talent plan; Extended market leadership and share gains in Australia/New Zealand; restructured Lion Nathan's international operations to set springboard for further international growth; and Introduced risk management systems to Lion Nathan Board, which enabled strategic and operational decisions in China, wine and non-core businesses. He has completed 3 Executive Leadership Programmes (Harvard Business School).
    Mr Salesh Balak Chief Financial OfficerCompany Secretary Dec 2018
    -
    Mr John Stewart Sharman Chief Executive Officer Jun 2020
    -
    John Stewart Sharman Chief Executive Officer
    -
    Salesh Balak Chief Financial OfficerCompany Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    No Top 20 Shareholder 0 0.00%

    Profile

    since

    Note